论文部分内容阅读
目的观察尤瑞克林治疗急性脑梗死的疗效及安全性。方法将106例急性脑梗死患者随机分为治疗组和对照组,对照组54例患者仅用基础用药,治疗组53例,除基础用药外,另用尤瑞克林0.15PNAU+0.9%氯化钠注射液100ml静脉滴注,1次/d,使用10～14d。评定患者治疗前后神经功能缺损程度(NIHSS)及残疾指数(mRSIndex),监测用药期间血压变化,检测肝、肾功能、纤维蛋白原、血小板、C反应蛋白,记录不良反应,并随访90dmRS。结果治疗后,两组患者NIHSS和mRS评分均降低(P<0.05),尤瑞克林治疗组NIHSS、mRS以及总有效率均优于对照组(P<0.05);治疗组90dmRS与治疗结束相比显著降低,与对照组90dmRS相比也显著降低(P<0.01)。结论尤瑞克林治疗急性脑梗死安全有效。
Objective To observe the efficacy and safety of urelin in the treatment of acute cerebral infarction. Methods 106 patients with acute cerebral infarction were randomly divided into treatment group and control group. In the control group, 54 patients were treated with basic drugs only. The treatment group consisted of 53 patients. In addition to the basal drugs, 0.15RUNA plus 0.9% chlorinated Sodium injection 100ml intravenous infusion, 1 / d, the use of 10 ~ 14d. The NIHSS and mRSIndex were measured before and after treatment. The blood pressure was monitored during the treatment. The liver and kidney function, fibrinogen, platelet and C-reactive protein were detected. The adverse reactions were recorded and followed up for 90 days. Results After treatment, the scores of NIHSS and mRS were decreased in both groups (P <0.05). The NIHSS, mRS and total effective rate in the two groups were significantly better than those in the control group (P <0.05) (P <0.01) compared with 90 dmRS in control group. Conclusion Erilecin treatment of acute cerebral infarction safe and effective.